Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AFFiRiS is planning to explore ProBioGen’s proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for Affitome-based vaccination concept.
Subscribe to our email newsletter
Under the contract with ProBioGen, AFFiRiS is expected to evaluate HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.
Using HuALN technology AFFiRiS anticipates accelerating the progression of its human vaccine candidates into clinical trials.
Walter Schmidt, CEO of AFFiRiS, said: “We have been looking for a system like the Human Artificial Lymph Node for quite a long time and are excited by the possibilities the system offers to test our peptide vaccine candidates which are delivered by our proprietary Affitome technology.”
Michael Schlenk, CEO of ProBioGen, said: “AFFiRiS with its technology in the vaccine field is an ideal partner to further underline the strengths of ProBioGen’s HuALN technology. We are very much looking forward to this co-operation.”